Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 16/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448203 | 0.87 | MRGPRX4 (0.66) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL1756369 | 0.84 | MRGPRX4 (0.81) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL14302571 | 0.82 | MRGPRX4 (0.60) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL4442742 | 0.82 | MRGPRX4 (0.62) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL4138759 | 0.81 | NR4A2 (0.81) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL4448031 | 0.81 | MRGPRX4 (0.65) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL9301215 | 0.80 | MRGPRX4 (1.00) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL3557707 | 0.80 | MRGPRX4 (0.57) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL22480783 | 0.79 | MRGPRX4 (1.00) | MRGPRX4TP53NFKB1NFKB2RELA | |
| SCHEMBL4447958 | 0.79 | MRGPRX4 (0.72) | MRGPRX4TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | claimed |
| EP-1819691-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2007-08-22 | — | — | EP | claimed |
| WO-2006058648-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | claimed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | claimed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1819691-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058648-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | MRGPRX4 1701/4885TP53 3823/4885PKM 399/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | MRGPRX4 1701/4885TP53 3823/4885PKM 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.